I've learned to steer clear of biotech SP over 10c until the...

First 15 Last

Share
Profile

Follow
Cuprum29

752 Posts.

76

15/05/24

11:44

Post #: 73833098
Share

Originally posted by pfeifer1982: ↑

Our CHM 0201 Vactosertib trial is recruiting again:
https://clinicaltrials.gov/study/NCT05400122?tab=table

And our new COO will be presenting at the Bio International Convention on in San Diego next month (5th June):
https://convention.bio.org/sessions/chimeric-therapeuticsMaybe we will get an update on CHM 2101 (CDH17) by then which is "scheduled to open in mid-2024."

As to the upcoming dilution, well, we all knew that money will be needed and after the last two rounds in short succession, the company had to go for a different approach. While we always hope for a partnership or licensing deal when it comes to funding, early stage biotech "surprises" you 9 times out of 10 with a Cap Raise or any other shape or form of dilution. But that 1 time out of 10, that's what we are all hoping for here given our current MC compared to other biotech companies in this space. Even the dilution won't stop this from taking off if our clinical data holds up.

Expand

I've learned to steer clear of biotech SP over 10c until the biotech is at least in P2 trials.
Unless its a wonder drug that attracts partners early on, you can be sure the SP will dip below 10c or even below 1c along the way.
Even the 2.4c buyers today may rue their purchase if SP dips below 1c (always a possibility with biotech).

CHM Price at posting: 2.4¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply